Bioatla, Inc. Stock Price, News & Analysis

BioAtla (BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has scheduled its Fourth Quarter and Full-Year 2024 financial results announcement for March 27, 2025.

The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial performance and provide business updates. Interested parties can access the call through domestic (800-245-3047) or international (203-518-9765) dial-in numbers using the Conference ID: BIOATLA.

BioAtla (NASDAQ: BCAB) has announced a registered direct offering of 9,679,158 common stock shares, each accompanied by a warrant to purchase one share at $1.19. The combined offering price is $0.9520 per share and warrant. The warrants will be exercisable after six months and expire in 5.5 years.

The offering is expected to generate approximately $9.2 million in gross proceeds, closing around December 20, 2024. The funds will support research and development initiatives, including key clinical programs: BA3182 Phase 1 dose escalation data (2Q25) and Phase 2 expansion data (1H26), and mecbotamab vedotin Phase 2B data in mKRAS NSCLC (1H26). Tungsten Advisors acted as the sole placement agent.

BioAtla presented data on Mecbotamab Vedotin (Mec-V) at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting. The study focused on patients with advanced non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS).

Results indicated improved median overall survival (OS) for Mec-V treated patients with mKRAS compared to wild-type KRAS (wtKRAS). One-year OS was 58% for mKRAS patients versus 23% for wtKRAS patients. Mec-V showed antitumor activity across 9 different mKRAS variants.

Key data highlights from the Phase 2 trial (NCT04681131) include:

• 78 patients enrolled, received Mec-V monotherapy or Mec-V + nivolumab.
• Patients had a median of 3 prior lines of therapy.
• 24 patients (30.7%) had mKRAS NSCLC.
• Median OS was not reached for mKRAS patients vs. 8.7 months for wtKRAS patients.
• 6 responses among 21 efficacy-evaluable mKRAS patients (ORR=28.6%).

AXL expression was highly associated with mKRAS NSCLC. Treatment was well tolerated with a manageable safety profile. A randomized trial of Mec-V in treatment-refractory mKRAS NSCLC is planned for 2025.

BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company, announced a poster presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting in Washington, DC, from December 13–15, 2024.

The presentation, titled Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC, will be delivered by a team of authors including Julia Rotow, Grace K. Dy, and others.

Details of the presentation include:

• Poster Number: PP01.03
• Session Type: Poster Reception
• Session Date and Time: Saturday, December 14, 2024, from 5:40 P.M. – 6:40 P.M. ET

Materials from the presentation will be available on the “Publication” section of BioAtla’s website after the event.

BioAtla (BCAB) reported Q3 2024 financial results and clinical progress. Key highlights include promising data from ozuriftamab vedotin Phase 2 trial in head and neck cancer showing 9-month median overall survival, and evalstotug demonstrating tumor reduction in melanoma patients. The company received FDA guidance for potential registrational trials in 2025. Q3 net loss was $10.6M, with revenue of $11.0M from a licensing agreement. R&D expenses decreased to $16.4M from $28.4M year-over-year. Cash position of $56.5M is expected to fund operations into early 2026.

BioAtla (BCAB), a clinical-stage biotechnology company developing Conditionally Active Biologic antibody therapeutics for solid tumors, will host a conference call and webcast on November 7, 2024, at 4:30 p.m. ET to discuss its third quarter 2024 financial results and business highlights. The financial results press release will be available before the conference call on the company's website. A replay will be accessible through the Investors section.

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown Convention Center in Houston, TX.

The presentation, titled 'Updated results from a phase 1 study of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors', is scheduled for Friday, November 8, 2024, at 9:00a CDT in Exhibit Halls AB. The presentation materials will be available on the 'Publication' section of BioAtla's website after the presentation concludes.

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced an upcoming oral presentation at the Society for Melanoma Research 21st International Congress (SMR) in New Orleans, LA, from October 10–13, 2024.

The presentation details are as follows:

• Title: Evalstotug (BA3071): a potent conditionally active biologic (CAB) anti-CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity
• Presenting Author: William Boyle, Ph.D.
• Session Category: Developmental Immunotherapy
• Date & Time: Friday, October 11th, 2024 from 8:00am–10:20am CDT

The abstract will be published in the 2024 SMR Abstract book and online in the PCMR journal. Presentation materials will be available on BioAtla's website after the presentation concludes.

BioAtla and Context Therapeutics have entered into an exclusive worldwide license agreement for the development and commercialization of BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody. Key points include:

1. Context obtains exclusive rights to BA3362
2. BioAtla to receive $15.0 million in upfront and near-term milestones
3. Potential for up to $118.5 million in additional clinical, regulatory, and commercial milestones, plus royalties on net sales
4. Context anticipates IND filing for BA3362 in mid-2026

This agreement allows BioAtla to focus on its lead clinical CAB programs while potentially advancing BA3362 under Context's leadership. The transaction aligns with Context's strategy of building a pipeline of TCE assets through strategic in-licensing or acquisition.